Del Mar-area drug delivery specialist Halozyme is talking about growth in years, not quarters, after telling investors that a run of acquisitions and licensing wins has positioned the company for what it calls a decade of expansion. Management has lifted its revenue outlook and now expects royalty income to top $1.1 billion in 2026, a milestone the company says is arriving earlier than it had previously projected. The strategy expands Halozyme’s drug delivery toolbox and could translate into more clinical trial launches, licensing deals and M&A activity centered in the San Diego life science hub.
Raised guidance and the numbers
In a Jan. 28 business update, Halozyme raised its preliminary, unaudited 2025 revenue estimate to a range of $1.385 billion to $1.4 billion and increased full-year 2026 guidance to $1.71 billion to $1.81 billion, with royalty revenue expected to land between $1.13 billion and $1.17 billion, according to PR Newswire. Company statements and local business coverage attribute the higher outlook to stronger than expected royalties from existing ENHANZE-enabled products combined with the impact of recent acquisitions, as reported by the San Diego Business Journal.
New platforms widen the toolbox
Halozyme completed its acquisition of Elektrofi in November 2025 and closed its deal for Surf Bio in late December, adding two hyperconcentration technologies that are intended to let drugmakers formulate biologic medicines at ultra-high concentrations suitable for single-shot subcutaneous dosing. The Elektrofi Hypercon microparticle method and Surf Bio’s spray-dry and proprietary excipient approach are aimed at achieving concentrations on the order of 400 to 500 mg/mL, which could shrink injection volumes and make autoinjectors more practical, according to reporting by BioPharma Dive. Company materials say these platforms extend Halozyme’s intellectual property estate into the mid 2040s and create new royalty streams beyond its ENHANZE franchise.
Pipeline and near-term catalysts
On a recent investor call, management said it expects to sign one to three new ENHANZE licensing agreements in 2026 and in each year after that, and plans to use free cash flow for selective acquisitions, CEO Helen Torley told investors, according to MarketBeat. Halozyme also said it anticipates that as many as six ENHANZE-enabled therapeutics will enter development this year and that two Hypercon partner programs are expected to begin clinical development by the end of 2026, milestones the company believes will support royalty growth into the late 2020s. Management’s longer term framework pushes projected 2028 royalty revenue into the $1.4 billion to $1.5 billion range as the new platforms and partner programs mature.
What it means locally
Halozyme lists its principal executive offices in the San Diego area and also maintains operations in Ewing, New Jersey, and Minnetonka, Minnesota, according to its SEC filings. The company reported about 350 full-time employees in its most recent annual report, a number that could grow if multiple development programs advance toward commercialization, per the U.S. Securities and Exchange Commission.
For San Diego’s life science community, the real proof will arrive if Hypercon formulations and ENHANZE programs turn into concrete clinical trial starts and, ultimately, a stream of royalties. Investors are expected to scrutinize Halozyme’s upcoming disclosures and any first-in-human filings tied to Hypercon and Surf Bio, looking for early signs that the company’s expanded delivery platform can be converted into the long-term revenue story management is pitching.
